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Ophthalmology Volume 121, Number 5, May 2014ranibizumab arm and 0.570.31 and 0.650.46 in the PDT arm,
respectively. The change in logMAR was signiﬁcantly different
between the 2 groups. (P ¼ 0.004) The frequency distribution of
the changes in logMAR compared with the baseline is shown in
Table 1 (available at www.aaojournal.org). Although several
patients in the PDT arm showed improvement in vision,
approximately 15% of the patients showed >6 lines of vision loss,
which affected the overall outcomes. To conﬁrm the integrity of
our results, we also analyzed the difference of the treatment effect
using the data of patients who completed the 24-month study (n ¼
40 in the PDT arm and n ¼ 38 in the ranibizumab arm). In these
patients, the baseline and ﬁnal logMAR were 0.480.26 and
0.380.39 in the ranibizumab arm and 0.560.31 and 0.580.43 in
the PDT arm, respectively. The change in logMAR was still
signiﬁcantly different between the 2 groups (P ¼ 0.025).
Both treatment options succeeded in reducing the retinal
thickness despite some ﬂuctuation. The baseline and ﬁnal central
retinal thickness were 366.8113.6 and 267.8142.2 mm in the
PDT arm (P< 0.001) and 418.9168.6 and 291.2129.3 mm in
the ranibizumab arm (P< 0.001), respectively. In contrast with
visual changes, the changes in central retinal thickness were not
different between the 2 arms (P ¼ 0.254).
The results of this study in patients with PCV showed that 3
monthly injections followed by as-needed injections of ranibizu-
mab can achieve better 24-month visual outcomes than PDT. This
result was similar to that obtained after 12 months of this trial.4
Although PDT is sometimes considered superior to anti-VEGF
therapy for the treatment of PCV because it can efﬁciently
induce regression of polypoidal lesions, the same may not be
implied with respect to the visual outcome. Continuous treatment
with anti-VEGF therapy, despite the inferior effect in achieving the
regression of polypoidal lesions, can prevent further visual loss in
comparison with PDT monotherapy.
Unfortunately, we did not investigate the effect of PDT com-
bined with ranibizumab because we could not recruit a sufﬁcient
number of patients to perform a 3-arm comparison, and the effect
of combined therapy, the optimal interval of ranibizumab and PDT
administration, and the retreatment protocol were not established
when we initiated the trial. Because several recent studies report
the efﬁcacy of combined therapy, future comparisons of anti-
VEGF agents with or without PDT must be performed.
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Drug Reaction: Incidence and Routine
Monitoring in the United KingdomSight-threatening side effects of medication are rare, but can lead to
a considerable individual and societal burden, especially when
severe and/or permanent. Because these events are so uncommon,
it is challenging to acquire data that clinicians can use to counsel
patients or that identify novel potential risks. Currently in the
United Kingdom, all serious suspected adverse drug reactions
(ADRs) and any drug-related side effect of a new (black triangle)
medication1 are “monitored” through the Medical and Health
product Regulatory Agency (MHRA) using the voluntary Yellow
Card Scheme2 to inform an anonymized national database.
Classiﬁcation of ocular ADRs is by eye condition with few
categories indicating functional vision. Thus, it is not possible to
estimate population incidence of visual impairment owing to
ADRs through this source.
We therefore undertook a prospective observational study
through the British Ophthalmological Surveillance Unit (BOSU),
the long-established national scheme providing anonymized case
ascertainment for epidemiologic studies of rare ophthalmic con-
ditions of public health importance.3 We report on this ﬁrst
systematic national study of incidence of diagnosis of visual
impairment owing to ADRs and comparative ascertainment by
the MHRA scheme.
Case Deﬁnition. Any child or adult newly diagnosed with sig-
niﬁcant visual loss suspected to be owing to anADR to any prescribed
medication (topical or systemic),4 including, bilateral or unilateral
Reportsvisual impairment, severe visual impairment or blind, namely,
distance acuity worse than Snellen 6/18 (logarithm of the minimum
angle of resolution, 0.48) in the better eye if bilaterally affected or
in the affected eye if unilateral (i.e., World Health Organization
modiﬁed taxonomy), or eligible for certiﬁcation as sight impaired
(partial sight) or severely sight impaired (blind), based on visual
ﬁelds. Patients with milder sight loss or those with raised intra-
ocular pressure or cataract owing to steroid treatment (i.e., known
and common dose-related side effects), were ineligible.
Case Ascertainment. Surveillance was undertaken over 24
months to February 2012, with 6-month follow-up data collec-
tion completed by November 2012. The BOSU sends a monthly
report card to all consultant ophthalmologists in the UK listing
all studies/conditions under surveillance. Ophthalmologists return
the card either notifying a “case” or conﬁrming they have no
cases to report (active versus passive surveillance). The BOSU
informs the study team, who send the reporting ophthalmologist
a standardized data collection form. There is no direct patient
contact. Completeness of ascertainment of eligible cases, evalu-
ated in prior studies using multiple sources and captur-
eerecapture analysis or other validation, ranges from 65% to
100% (personal communication, B. Foot, September 2013, Sci-
entiﬁc Co-ordinator BOSU).3 There was no suitable additional
source for the present study.
Procedures. At notiﬁcation, information was requested on the
patient’s visual status prior and post the suspected ADR, the spe-
ciﬁc ophthalmic condition attributable to the ADR, preexisting eye
disease, all medications being used at the time, the name of the
suspected drug, and its duration of administration, dose and
administration route.
A follow-up questionnaire sent 6 months later collected infor-
mation on both the permanency of the visual impairment reported
and the probability of the causality of the ADR, using the World
Health Organization-Uppsala Monitoring Centre (UMC) criteria.
At follow-up, reporting clinicians were asked if the suspected ADR
had also been reported additionally to the MHRA.
Statistical Methods. We report incidence based on cases with
“permanent” visual impairment. For completeness, we report
separately on “temporary” visual impairment, that is, patients
whose visual function had improved above the study threshold at 6
month follow-up. Annual incidence rates were estimated using the
Ofﬁce of National Statistics 2011 Census population estimates for
the UK as the denominator.
There were 36 eligible cases were reported between March
2010 and February 2012. Of these, 18 had permanent visual
impairment conﬁrmed (permanent cases), and 13 had temporary
visual impairment. Outcome was not available in 5 cases, for
various reasons.
The annual incidence of permanent visual impairment owing to
suspected ADR was 0.2/1 000 000 adults (95% conﬁdence interval,
0.10e0.37 per 1 000 000). Assuming the unconﬁrmed cases to be
permanent, the estimate increases to 0.25 per 1 000 000 adults
(95% conﬁdence interval, 0.17e0.37), giving an estimated range
for the annual incidence of 0.1 to 0.37 per 1 000 000 adults. There
were no cases in children.
Report to the MHRA (Yellow Card Monitoring Scheme).
Only 7 of the 17 permanent cases (41%) were deﬁnitely known to
have been reported to the MHRA (1 case, no information). Five
had not been reported and reporting status for 5 was unknown.Information was available for 9 of 13 of the temporary cases: 5 of
the 9 (56%) were reported to the MHRA, 2 not reported, and 2
reporting status unknown. For drugs with well-established adverse
ocular side effects, there was inconsistent reporting to the MHRA.
For example, all permanent cases suspected to be owing to amio-
darone (n ¼ 2) or quinine (n ¼ 2) were reported, but only 1 of 7
permanent cases suspected to be owing to ethambutol.
Our study serves to reassure clinicians and patients alike that
vision impairment owing to ocular ADRs remains very uncommon,
affecting <4 of every 10 million adults annually and is assumed to
be even rarer in children. It also highlights the on-going challenges
in monitoring ADRs that underlie the incomplete evidence base for
recommendations about screening. Further research on individual
drugs are necessary to address this.
Our ﬁndings suggest that currently the use of the MHRA
Yellow Card Scheme for monitoring these events is inefﬁcient.
Notably, among the 236 reports of ADRs owing to ethambutol
received by the MHRA since 1963, 4 (1.8%) reported optic neu-
ropathy5; 3 of these were in the past 5 years, which suggests prior
underreporting. Moreover, because 7 cases of optic neuropathy
attributed to ethambutol were identiﬁed by our study over 24
months it is possible that active versus passive surveillance
additionally prompted clinicians. If so, this suggests there is
potential to increase the effectiveness of the MHRA Yellow Card
Scheme by enhanced communication with clinicians.
For drugs that are known to have adverse ocular side effects or
have known direct effects that can be reversed with immediate clin-
ical management, reporting these events to theMHRAmay not be the
clinical priority. However, if the data collected were evaluated and
reported back to clinicians regularly, there may be a better role for the
MHRA system to monitor novel ocular ADR events, in partnership
with clinicians and serve as a reliable sentinel surveillance system.
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Dataset (N cases ¼ 3108,
SNP Position Reference Allele Pooled OR (95% CI)
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rs10278782 116147401 G 1.22 (1.10, 1.35)
rs3779512 116171063 T 1.15 (1.06, 1.25)
1Abbreviations: CAV1 ¼ caveolin 1; CAV2 ¼ caveolin 2; CI ¼ conﬁdence in
National Eye Institute Glaucoma Human Genetics Collaboration; OR ¼ odds
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in Meta-analysis of the Combined GLAUGEN and NEIGHBOR
N controls ¼ 3430)1,2
GLAUGEN P Value NEIGHBOR P Value
Pooled
P Value3,4
0.003 1.89  105 2.61 3 107
0.003 2.54  105 3.58 3 107
9.13  104 6.77  104 3.69 3 106
7.80  104 0.001 5.78 3 106
0.002 6.70  104 6.43 3 106
0.001 0.001 1.09 3 105
0.007 0.001 2.98 3 105
0.007 0.002 6.68 3 105
0.02 0.002 1.49 3 104
0.006 0.03 7.60 3 104
terval; GLAUGEN ¼ Glaucoma Genes and Environment; NEIGHBOR ¼
ratio; POAG ¼ primary open angle glaucoma; SNPs ¼ single nucleotide
controls.
analyses ¼ 65; 0.05/65 ¼ 7.7  104) are in bold.
Ps.
